Martens Rachel Yap 4

What Happened Rachel Martens (listed in the filing as Martens Rachel Yap), SVP, Partnerships & Corp Strat at Lexicon Pharmaceuticals (LXRX), received two restricted stock unit (RSU) awards on 2026-02-12 totaling 484,360 RSUs (193,740 and 290,620). The awards were reported at $0.00 per unit because they are derivative awards (contingent rights to receive common shares upon vesting), not open‑market purchases.

Key Details

• Transaction date: 2026-02-12; Filing date (Form 4): 2026-02-17 — appears to be filed later than the typical 2-business-day Form 4 deadline.
• Transaction code: A (Grant/Award) — RSUs, not an immediate purchase or sale.
• Amounts granted: 193,740 RSUs and 290,620 RSUs (total 484,360 RSUs). Reported price: $0.00 per unit.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F2: Vesting schedule: 1/3 of the RSUs vest on February 28 of each of the three years following the year of grant.
  • F3 (present in filing) describes option vesting (25% after one year, then monthly), but no option exercise or option grant is reported in these transactions.
• No indication in the filing that shares were sold or withheld for taxes at grant.

Context RSUs are a form of compensation that convert into common shares only after vesting per the stated schedule; they do not represent immediate voting shares or cash value until vested (though they have potential future economic value tied to LXRX stock price). Such awards are common for executive compensation and do not by themselves indicate the insider is buying or selling stock. The apparent late filing could be procedural; late Form 4s can matter to investors tracking timely insider activity.